Literature DB >> 24793699

The evolving role of nuclear transporters in cancer.

Asfar S Azmi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24793699     DOI： 10.1016/j.semcancer.2014.04.011

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN： 1044-579X            Impact factor:   15.707


× No keyword cloud information.
  8 in total

1.  A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K.

Authors:  Iraia García-Santisteban; Igor Arregi; Marián Alonso-Mariño; María A Urbaneja; Juan J Garcia-Vallejo; Sonia Bañuelos; Jose A Rodríguez
Journal:  Cell Mol Life Sci       Date:  2016-06-16       Impact factor: 9.261

2.  Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC).

Authors:  Misako Nagasaka; Mohammad Fahad B Asad; Mohammed Najeeb Al Hallak; Md Hafiz Uddin; Ammar Sukari; Yasmine Baca; Joanne Xiu; Dan Magee; Hirva Mamdani; Dipesh Uprety; Chul Kim; Bing Xia; Stephen V Liu; Jorge J Nieva; Gilberto Lopes; Gerold Bepler; Hossein Borghaei; Michael J Demeure; Luis E Raez; Patrick C Ma; Sonam Puri; W Michael Korn; Asfar S Azmi
Journal:  Lung Cancer       Date:  2021-08-27       Impact factor: 6.081

Review 3.  The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma.

Authors:  Mark Sellin; Stephanie Berg; Patrick Hagen; Jiwang Zhang
Journal:  Transl Oncol       Date:  2022-06-01       Impact factor: 4.803

Review 4.  F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.

Authors:  Ammar Sukari; Irfana Muqbil; Ramzi M Mohammad; Philip A Philip; Asfar S Azmi
Journal:  Semin Cancer Biol       Date:  2016-01-21       Impact factor: 15.707

Review 5.  The nuclear export protein XPO1 - from biology to targeted therapy.

Authors:  Asfar S Azmi; Mohammed H Uddin; Ramzi M Mohammad
Journal:  Nat Rev Clin Oncol       Date:  2020-11-10       Impact factor: 66.675

6.  Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.

Authors:  Asfar S Azmi; Husain Yar Khan; Irfana Muqbil; Amro Aboukameel; Jasper E Neggers; Dirk Daelemans; Amit Mahipal; Gregory Dyson; Mandana Kamgar; Mohammad Najeeb Al-Hallak; Anteneh Tesfaye; Steve Kim; Vinod Shidham; Ramzi M Mohammad; Philip A Philip
Journal:  Clin Cancer Res       Date:  2019-12-12       Impact factor: 12.531

7.  Leukemia-Associated Mutations in Nucleophosmin Alter Recognition by CRM1: Molecular Basis of Aberrant Transport.

Authors:  Igor Arregi; Jorge Falces; Anne Olazabal-Herrero; Marián Alonso-Mariño; Stefka G Taneva; José A Rodríguez; María A Urbaneja; Sonia Bañuelos
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

8.  Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.

Authors:  Husain Yar Khan; James Ge; Misako Nagasaka; Amro Aboukameel; Gabriel Mpilla; Irfana Muqbil; Mark Szlaczky; Mahmoud Chaker; Erkan Baloglu; Yosef Landesman; Ramzi M Mohammad; Asfar S Azmi; Ammar Sukari
Journal:  Int J Mol Sci       Date:  2019-12-29       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.